Document is current

Article History

Received: 4 June 2024

Accepted: 12 August 2024

First Online: 26 August 2024

Declarations

:

: An online consent to participate in the survey was collected from all the participants before they started answering the questions. Ethics approval is not applicable.

: Not applicable.

: AMK has received research grants and/or consulting/speaker’s fees from AbbVie, UCB, Pfizer, Janssen, Eli Lilly, and Organon. ALBPD has received consulting/speaker’s fees from AbbVie, Novartis, Celltrion, Janssen, Eli Lilly, GSK, Astra Zeneca, Boehringer-Ingelheim, and Fresenius-Kabi Brazil. CVB has received research grants and/or consulting/speaker’s fees from AbbVie, Celltrion, Janssen, Lilly, and Organon. DSD has received consulting/speaker’s fees from AbbVie, Janssen, and Amgen. IMML has received research grants and/or consulting/speaker’s fees from Abbvie, Amgen, Boehring, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and Sandoz. KRB has received consulting/speaker’s fees from AbbVie, Pfizer, Novartis, and UCB. LMHM has received research grants and/or consulting/speaker’s fees from AbbVie, Celltrion, Janssen, Lilly, Organon, Pfizer, Novartis, UCB, Boehringer-Ingelheim, Astra Zeneca, and GSK. MHB has received funds, all paid to her host institution through a grant from Gilead and consultancy and honoraria from AbbVie, Arxx Therapeutics, Boehringer Ingelheim, CESAS Medical, Gilead, Galapagos, Gilead, Pfizer Ltd, and Medistream. EAM is an AbbVie employee and may own stock or options. RMX has received research grants and/or consulting/speaker’s fees from AbbVie, Janssen, UCB, Pfizer, Novartis, Amgen.